Acesso to information
logo fiocruz 1Contact Fiocruz

About Fiocruz and Bio-Manguinhos

castelo fiocruz torre bandeiraFiocruz: reference in science and technology in health

Created in 1900, the Oswaldo Cruz Foundation (Fiocruz) promotes health, generates scientific and technological knowledge and stands as an agent of citizenship. Under the Ministry of Health, the institution articulates social policies to a development model that aims to ensure the strengthening and consolidation of the Unified Health System – “Sistema Único de Saúde” (SUS), ensuring greater public access to health. Recognized for its expertise in formulating strategies, offering products as well as promoting scientific and teaching activities, Fiocruz plays a vital role in the national development. All these achievements are the result of the performance of nearly 13,000 professionals, committed to the constant improvement of the public health system.
Its headquarters, like most of its units, are located in Rio de Janeiro, in a campus of 800,000 m². Even so, the Foundation has regional units and representative offices in 11 states. It also has, in Maputo, capital of Mozambique, an office to coordinate, monitor and evaluate health programs developed in cooperation with African countries.


Bio-Manguinhos: 40 years of an Institute under in constant renovation

bio manguinhos fiocruz horizontal 2015 wide

An institution at the service of life. Such definition suits the Institute of Technology in Immunobiologicalsy (Bio-Manguinhos), a unit of Fiocruz that has been producing ed vaccines, diagnosis reagents for diagnosis and biopharmaceuticals since 1976, year of its creation. For 40 years, the Institute has been expanding the population´s access to health care by offering new products to prevent, diagnose and treat diseases. This action goes beyond the borders of the country, benefiting developing countries, especially in Africa and Latin America.

In order to establish itself as the largest public laboratory of the country, Bio-Manguinhos wrote parts of the history of public health in Brazil. It played a decisive role in the eradication of polio in the country and the Americas thanks to the establishment of partnerships with Japanese institutions with the aim to produce a vaccine against the disease. It was also fundamental in controlling measles and yellow fever, thus becoming a leading producer of the vaccines in the world, having exported to over 70 countries. In order to keep its leading role, the Institute seeks for renewal and innovation.

bio manguinhos cipbr bandeira

Partnerships with institutions - public and private - ensure technology transfer agreements and technological development, contributing to the development of their its projects and a faster incorporation of production know how ledge. Compliance with the requirements of the Good Manufacturing Practices (GMP) – “Boas Práticas de Fabricação (BPF)” – in addition to the quality certification of its laboratories render the Institute a strategic agent under the Economic Industrial Health Complex. – “Complexo Econômico Industrial da Saúde (CEIS)”. The 14 “Productive Development Partnerships” – PDPs - – “Parcerias para Desenvolvimento Produtivo (PDPs)” – under development in the unit are proof of this commitment. Thanks to PDPs like these, the federal government offers a wider range of products through the Unified Health System.

The portfolio of the Institute grows annually. It consists of 31 products: 10 vaccines, 16 reagents for diagnosis reagents and 5 biopharmaceuticals. Every year, millions of units are provided to the programs of the Ministry of Health. Bio-Manguinhos has expanded its physical infrastructure in order to meet the growing demand of the government in the health field, especially with regard to biotechnological drugs. Two new plants are under construction: Santa Cruz, on the west of Rio de Janeiro, and Eusebius, in the metropolitan area of Fortaleza, state of Ceará (CE). Both campuses will gain modern facilities, capable of multiplying the production scale of three product lines, thus raising the status of the Institute to as a world producer.

Keeping this role has required changes in order for the Institute to grow sustainably. Since 2012, Bio-Manguinhos has worked in the modification of its legal form towards a public company, which will allow more efficiency in meeting public health demands. The process is being conducted by the Board of the Institute and the President of Fiocruz, together with the Ministries of Health, Finance and Planning.

Bio-Manguinhos seeks, through renovation and innovation, the way to maintain its leading position in the market, paving an even more promising future.

 

Hosted by

 

 

bio manguinhos selo 40 anoslogo fiocruzlogo suslogo mslogo ms governo federal
Strategic Partners

 

logos parceiros